Patents Assigned to CuRNA, Inc.
  • TREATMENT OF NUCLEAR FACTOR (ERYTHROID-DERIVED 2)-LIKE 2 (NRF2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO NRF2
    Publication number: 20170145411
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Nuclear factor (erythroid-derived 2)-like 2 (NRF2), in particular, by targeting natural antisense polynucleotides of Nuclear factor (erythroid-derived 2)-like 2 (NRF2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of NRF2.
    Type: Application
    Filed: September 20, 2016
    Publication date: May 25, 2017
    Applicant: CuRNA, Inc.
    Inventors: Joseph COLLARD, Olga KHORKOVA SHERMAN, Carlos COITO
  • Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
    Patent number: 9624493
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Atonal homolog 1 (ATOH1), in particular, by targeting natural antisense polynucleotides of Atonal homolog 1 (ATOH1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of ATOH1.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: April 18, 2017
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Treatment of tristetraproline (TTP) related diseases by inhibition of natural antisense transcript to TTP
    Patent number: 9611477
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tristetraproline (TTP), in particular, by targeting natural antisense polynucleotides of Tristetraproline (TTP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of TTP.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: April 4, 2017
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Treatment of frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN
    Patent number: 9593330
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Frataxin (FXN), in particular, by targeting natural antisense polynucleotides of Frataxin (FXN). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of FXN.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: March 14, 2017
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to DMD family
    Patent number: 9533004
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Dystrophin family, in particular, by targeting natural antisense polynucleotides of Dystrophin family. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of DMD family.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: January 3, 2017
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Treatment of ‘IQ motif containing gtpase activating protein’ (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP
    Patent number: 9528110
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of ‘IQ motif containing GTPase activating protein’ (IQGAP), in particular, by targeting natural antisense polynucleotides of ‘IQ motif containing GTPase activating protein’ (IQGAP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IQGAP.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: December 27, 2016
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito
  • Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
    Patent number: 9512427
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of an Antiviral gene, in particular, by targeting natural antisense polynucleotides of an Antiviral gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Antiviral genes.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: December 6, 2016
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • TREATMENT OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO VEGF
    Publication number: 20160340678
    Abstract: Oligonucleotide compounds modulate expression and/or function of Vascular Endothelial Growth Factor (VEGF) polynucleotides and encoded products thereof. Methods for treating diseases associated with Vascular Endothelial Growth Factor (VEGF) comprise administering one or more Oligonucleotide compounds designed to inhibit the VEGF natural antisense transcript to patients.
    Type: Application
    Filed: August 5, 2016
    Publication date: November 24, 2016
    Applicant: CuRNA, Inc.
    Inventors: Joseph COLLARD, Olga KHORKOVA SHERMAN
  • Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
    Patent number: 9464287
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Nuclear factor (erythroid-derived 2)-like 2 (NRF2), in particular, by targeting natural antisense polynucleotides of Nuclear factor (erythroid-derived 2)-like 2 (NRF2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of NRF2.
    Type: Grant
    Filed: March 16, 2010
    Date of Patent: October 11, 2016
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito
  • TREATMENT OF PYRROLINE-5-CARBOXYLATE REDUCTASE 1 (PYCR1) RELATED DISEASE BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO PYCR1
    Publication number: 20160289759
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Pyrroline-5-carboxylate reductase 1 (PYCR1), in particular, by targeting natural antisense polynucleotides of Pyrroline-5-carboxylate reductase 1 (PYCR1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of PYCR1.
    Type: Application
    Filed: June 7, 2016
    Publication date: October 6, 2016
    Applicant: CuRNA, Inc.
    Inventors: Joseph COLLARD, Olga KHORKOVA SHERMAN
  • TREATMENT OF DISCS LARGE HOMOLOG (DLG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO DLG
    Publication number: 20160281088
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Discs large homolog (DLG), in particular, by targeting natural antisense polynucleotides of Discs large homolog (DLG). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of DLG.
    Type: Application
    Filed: June 7, 2016
    Publication date: September 29, 2016
    Applicant: CuRNA, Inc.
    Inventors: Joseph COLLARD, Olga KHORKOVA SHERMAN, Carlos COITO
  • TREATMENT OF COLONY-STIMULATING FACTOR 3 (CSF3) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENE TRANSCRIPT TO CSF3
    Publication number: 20160273037
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Colony-stimulating factor 3 (CSF3), in particular, by targeting natural antisense polynucleotides of Colony-stimulating factor 3 (CSF3). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of CSF3.
    Type: Application
    Filed: June 7, 2016
    Publication date: September 22, 2016
    Applicant: CuRNA, Inc.
    Inventors: Joseph COLLARD, Olga KHORKOVA SHERMAN
  • Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF
    Patent number: 9410155
    Abstract: Oligonucleotide compounds modulate expression and/or function of Vascular Endothelial Growth Factor (VEGF) polynucleotides and encoded products thereof. Methods for treating diseases associated with Vascular Endothelial Growth Factor (VEGF) comprise administering one or more Oligonucleotide compounds designed to inhibit the VEGF natural antisense transcript to patients.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: August 9, 2016
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG
    Patent number: 9394542
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Discs large homolog (DLG), in particular, by targeting natural antisense polynucleotides of Discs large homolog (DLG). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorder associated with the expression of DLG.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: July 19, 2016
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito
  • Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1
    Patent number: 9382543
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Pyrroline-5-carboxylate reductase 1 (PYCR1), in particular, by targeting natural antisense polynucleotides of Pyrroline-5-carboxylate reductase 1 (PYCR1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of PYCR1.
    Type: Grant
    Filed: January 7, 2015
    Date of Patent: July 5, 2016
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3
    Patent number: 9382538
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Colony-stimulating factor 3 (CSF3), in particular, by targeting natural antisense polynucleotides of Colony-stimulating factor 3 (CSF3). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of CSF3.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: July 5, 2016
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Treatment of adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an adiponectin (ADIPOQ)
    Patent number: 9290766
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of an Adiponectin (ADIPOQ), in particular, by targeting natural antisense polynucleotides of an Adiponectin (ADIPOQ). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Adiponectins (ADIPOQ)s.
    Type: Grant
    Filed: April 25, 2015
    Date of Patent: March 22, 2016
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
    Patent number: 9267136
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Pancreatic Developmental gene, in particular, by targeting natural antisense polynucleotides of a Pancreatic Developmental gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Pancreatic Developmental genes.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: February 23, 2016
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Treatment of insulin gene (INS) related diseases by inhibition of natural antisense transcript to an insulin gene (INS)
    Patent number: 9234199
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of an Insulin gene (INS), in particular, by targeting natural antisense polynucleotides of an Insulin gene (INS). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Insulin Gene (INS).
    Type: Grant
    Filed: August 5, 2010
    Date of Patent: January 12, 2016
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
    Patent number: 9222088
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Alpha-L-Iduronidase (IDUA), in particular, by targeting natural antisense polynucleotides of Alpha-L-Iduronidase (IDUA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IDUA.
    Type: Grant
    Filed: October 20, 2011
    Date of Patent: December 29, 2015
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito, Gang Shen